Funding for this research was provided by:
Innovative Medicines Initiative (806968)
Received: 18 March 2021
Accepted: 8 August 2021
First Online: 16 August 2021
: The use of Optum Claims was reviewed by the New England Institutional Review Board (IRB) and were determined to be exempt from broad IRB approval.
: Not applicable.
: JMR, PBR and MJS are employees of Janssen R&D and shareholders of Johnson and Johnson.